Gritstone bio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Gritstone bio şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-1,366.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-1,366.6%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Jun 11

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: GRTS.Q şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: GRTS.Q şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Gritstone bio Piyasaya Karşı Temettü Getirisi

GRTS.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (GRTS.Q)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (GRTS.Q) (3 yıla kadar)	0%

Önemli Temettü: GRTS.Q şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, GRTS.Q şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: GRTS.Q şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: GRTS.Q herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Gritstone bio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

New major risk - Share price stability

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Consensus revenue estimates decrease by 60%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Price target decreased by 16% to US$4.33

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Consensus revenue estimates decrease by 17%, EPS upgraded

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Consensus revenue estimates decrease by 37%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 12% to US$8.80

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Consensus revenue estimates fall by 40%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Price target increased by 20% to US$10.34

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Price target increased by 20% to US$10.34

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Consensus revenue estimates fall by 53%

Price target decreased by 14% to US$8.60

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.75

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Price target decreased to US$10.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone reaches six-month high on publication of data for cancer vaccine

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Consensus revenue estimates increase by 14%

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Price target increased to US$16.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio announces $80M credit facility

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

Price target increased to US$16.00

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$14.67

Less than half of directors are independent

Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

Consensus revenue estimates fall by 57%

Full year 2021 earnings: EPS misses analyst expectations

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate